To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Merck's Premyvis letermovir for CMV

FDA approved once-daily oral and IV formulations of Prevymis letermovir (MK-8228) from Merck & Co.

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE